Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review of bench, animal, and mechanistic research without human trial data.
PubMed 38196001 · doi:10.1007/s00702-023-02730-6
What was done
This narrative review summarizes literature regarding the molecular interactions among dopamine oxidation, alpha-synuclein pathology, monoamine oxidase activity, and mitochondrial dysfunction in Parkinson's disease pathogenesis and experimental models.
What was found
The abstract reports no numerical data. Dopamine oxidation catalyzed by monoamine oxidase generates reactive oxygen species, toxic aldehydes, and quinones that enhance alpha-synuclein fibrillization and mitochondrial accumulation. Alpha-synuclein reciprocally impairs dopamine synthesis and alters monoamine oxidase expression and activity. In experimental models, monoamine oxidase-B inhibitors (rasagiline and selegiline) suppress alpha-synuclein fibrillization and confer neuroprotection.
Why it matters
It highlights a bidirectional toxic feedback loop between dopamine metabolism and alpha-synuclein within mitochondria, outlining mechanistic targets for potential disease-modifying therapies in Parkinson's disease.
Limits
The abstract contains no primary quantitative data, sample sizes, or systematic review methodology. Reported mechanisms derive largely from bench and experimental models that may not fully reflect clinical disease progression in humans.
Cited by
- contradicts Dopamine binds to monoamine oxidase on the outer surface of mitochondria to initiate electron transport and increase ATP availability.